It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that despite the large size of the viral RNA genome (~30 kb), infectious full-length cDNA is readily assembled in vitro by a circular polymerase extension reaction (CPER) methodology without the need for technically demanding intermediate steps. Overlapping cDNA fragments are generated from viral RNA and assembled together with a linker fragment containing CMV promoter into a circular full-length viral cDNA in a single reaction. Transfection of the circular cDNA into mammalian cells results in the recovery of infectious SARS-CoV-2 virus that exhibits properties comparable to the parental virus in vitro and in vivo. CPER is also used to generate insect-specific Casuarina virus with ~20 kb genome and the human pathogens Ross River virus (Alphavirus) and Norovirus (Calicivirus), with the latter from a clinical sample. Additionally, reporter and mutant viruses are generated and employed to study virus replication and virus-receptor interactions.
Here the authors describe a simple reverse genetics method that relies on overlapping cDNA fragments for generation of positive-strand viruses including SARS-CoV-2 and characterize them in vitro and in vivo.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
2 University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); National Environmental Agency, Microbiology and Molecular Epidemiology Division, Environmental Health Institute, Singapore, Singapore (GRID:grid.452367.1) (ISNI:0000 0004 0392 4620)
4 QIMR Berghofer Medical Research Institute, Herston, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
5 Queensland Department of Health, Queensland Health Forensic & Scientific Services, Coopers Plains, Australia (GRID:grid.415606.0) (ISNI:0000 0004 0380 0804)
6 Monash University, Infection & Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
7 University of Queensland, School of Medicine, Kelvin Grove, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
8 University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537); Global Virus Network Centre of Excellence, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1003.2)
9 QIMR Berghofer Medical Research Institute, Herston, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); Global Virus Network Centre of Excellence, Australian Infectious Diseases Research Centre, Brisbane, Australia (GRID:grid.1049.c)